All lobbying filings

Prime Therapeutics

Prime Therapeutics filed a Q3 report for Prime Therapeutics on October 16, 2025.

Lobbying for Prime Therapeutics

As filed: PRIME THERAPEUTICS for PRIME THERAPEUTICS.

All filings by Prime Therapeutics · Everything Prime Therapeutics has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 16, 2025

Expenses

$100,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Minnesota

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs

Medicare/Medicaid

S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards

Trade (domestic/foreign)

Tariffs on pharmaceuticals.

Bills named in this filing 7

S. 891
Bipartisan Health Care Act
H.R. 10445
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
H.R. 2214
DRUG Act
H.R. 5378
Lower Costs, More Transparency Act
S. 526
Pharmacy Benefit Manager Transparency Act of 2025
H.R. 4231
Treat and Reduce Obesity Act of 2025
H.R. 4317
PBM Reform Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.